SAN DIEGO–(BUSINESS WIRE)–Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of …
Tag Archives: inflammatory diseases
November, 2018
October, 2018
-
10 October
Biohaven Acquires Option to License the University of Connecticut’s Investigational Agent for Inflammatory and Autoimmune Diseases
NEW HAVEN, Conn., Oct. 9, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it signed an exclusive, worldwide option and license agreement with the University of Connecticut for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein (MT). Extracellular MT has been implicated in …
May, 2018
-
1 May
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease …
December, 2017
-
15 December
FDA Approves Pfizer’s Ixifi, a Biosimilar to Remicade
Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* for all eligible indications of the reference product.1 The FDA has approved IXIFI as …
July, 2017
-
20 July
Ablynx and Sanofi Partner to Develop Nanobody-Based Therapeutics for Inflammatory Diseases
GHENT, Belgium, 20 July 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercializing Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases. This collaboration gives Sanofi access …
February, 2017
-
24 February
New Assay May Lead to a Cure for Debilitating Inflammatory Joint Disease
Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at NYU Langone Medical Center and the University of Pittsburgh. Known as autoantibodies and produced by the immune system’s B cells, …
-
15 February
X-Chem Expands its Collaboration with Janssen in Inflammatory Diseases
WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, …
January, 2017
-
18 January
FDA and EMA Accept Boehringer Ingelheim’s Biosimilar Candidate to Humira for Review
Ingelheim, Germany, January 18, 2017 – Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). “We believe that if approved, BI 695501 can provide a valuable …
December, 2016
-
14 December
Invisible Symptoms Impact Rheumatoid Arthritis Patients’ Lives, Hinder Diagnosis
Philadelphia, Dec. 14, 2016 – Rheumatoid Arthritis In America 2016, a national survey by Health Union of more than 3,100 individuals who identified as having rheumatoid arthritis (RA), reveals that initial symptoms are often invisible to others, with respondents experiencing more than six on average. A summary infographic is also …
November, 2016
-
30 November
Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study
CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …